ANGLE PLC (AIM:AGL, OTCQX:ANPCY) announced independent findings from Weill Cornell Medicine, which showcased its Parsortix-based HER2 workflow at the San Antonio Breast Cancer Symposium.
The study, involving 16 metastatic breast cancer patients, confirmed ANGLE's research, highlighting the potential of minimally invasive HER2 testing for treatment stratification.
The Parsortix system identified HER2-positive circulating tumour cells (CTCs) even in patients with HER2-negative tissue biopsies.
This approach could expand access to HER2 antibody-drug conjugates, benefiting over 60% of patients currently excluded from such treatments.
ANGLE's Chief Scientific Officer, Karen Miller, said: "We are pleased to see new data that supports the utility of quantitative HER2 assessment on CTCs isolated using the Parsortix system and independently validates ANGLE's own findings from our HER2 assay development programme.
"HER2 status is known to change in up to 38% of breast cancer patients. As such real-time quantitative HER2 assessment is crucial for both effective treatment and to support patient stratification for clinical trials and insight into dynamic changes in HER2 status which may correlate to therapeutic response."